Telemus Capital LLC Lowers Stake in AbbVie Inc. (NYSE:ABBV)

Telemus Capital LLC lowered its stake in shares of AbbVie Inc. (NYSE:ABBVFree Report) by 10.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,559 shares of the company’s stock after selling 1,567 shares during the period. Telemus Capital LLC’s holdings in AbbVie were worth $1,827,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Johnson & White Wealth Management LLC purchased a new stake in shares of AbbVie during the first quarter valued at about $721,000. Sand Hill Global Advisors LLC boosted its holdings in AbbVie by 0.4% in the first quarter. Sand Hill Global Advisors LLC now owns 18,755 shares of the company’s stock worth $2,989,000 after acquiring an additional 68 shares in the last quarter. Chesapeake Wealth Management boosted its holdings in AbbVie by 21.4% in the fourth quarter. Chesapeake Wealth Management now owns 13,083 shares of the company’s stock worth $2,114,000 after acquiring an additional 2,305 shares in the last quarter. Quintet Private Bank Europe S.A. purchased a new stake in shares of AbbVie during the first quarter worth about $6,686,000. Finally, Capital Market Strategies LLC increased its holdings in shares of AbbVie by 5.0% during the first quarter. Capital Market Strategies LLC now owns 12,027 shares of the company’s stock valued at $1,917,000 after acquiring an additional 575 shares in the last quarter. Hedge funds and other institutional investors own 67.86% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV opened at $152.12 on Friday. The company has a 50 day moving average price of $146.42 and a 200-day moving average price of $147.50. AbbVie Inc. has a 1-year low of $130.96 and a 1-year high of $168.11. The firm has a market cap of $268.50 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.74 and a beta of 0.58. The company has a debt-to-equity ratio of 4.33, a current ratio of 0.89 and a quick ratio of 0.77.

AbbVie (NYSE:ABBVGet Free Report) last released its quarterly earnings data on Thursday, July 27th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. AbbVie had a net margin of 15.50% and a return on equity of 151.29%. The company had revenue of $13.87 billion during the quarter, compared to analysts’ expectations of $13.52 billion. Equities research analysts forecast that AbbVie Inc. will post 11.03 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a $1.48 dividend. This represents a $5.92 annualized dividend and a yield of 3.89%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is currently 121.81%.

Insider Transactions at AbbVie

In related news, CEO Richard A. Gonzalez sold 18,500 shares of AbbVie stock in a transaction on Monday, July 31st. The shares were sold at an average price of $149.15, for a total value of $2,759,275.00. Following the sale, the chief executive officer now owns 625,294 shares of the company’s stock, valued at approximately $93,262,600.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ABBV shares. TheStreet upgraded shares of AbbVie from a “c+” rating to a “b” rating in a research note on Monday, August 28th. Credit Suisse Group cut their target price on AbbVie from $170.00 to $160.00 in a research report on Wednesday, July 12th. assumed coverage on AbbVie in a research note on Thursday, August 17th. They set a “strong-buy” rating on the stock. Piper Jaffray Companies raised their price objective on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Finally, William Blair initiated coverage on shares of AbbVie in a report on Tuesday, July 25th. They issued a “market perform” rating on the stock. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from, the stock currently has an average rating of “Moderate Buy” and an average price target of $165.79.

Check Out Our Latest Stock Report on ABBV

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Further Reading

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.